

Servier India introduces targeted therapy in oncology for rare IDH1-mutated AML and cholangiocarcinoma

05 June 2025 | News

Marks an important development in oncology, providing a treatment option for patients with AML and cholangiocarcinoma in India



Servier India, a subsidiary of the leading French pharmaceutical Servier Group, has announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation.

Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication.

Acute myeloid leukemia (AML) is a challenging hematological malignancy. Studies indicate that only about 30–40% of AML patients in India receive adequate treatment, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced.

IDH1 mutation occurs in approximately 7–14% of AML patients in India, making targeted mechanisms especially relevant for this subset.

“This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and

advancing cancer care in India.”, highlighted Dr Pranav Sopory, Medical and Patient Affairs Director, Servier India.